Literature DB >> 25506356

IRF4 and IRF8: Governing the virtues of B Lymphocytes.

Vipul Shukla1, Runqing Lu1.   

Abstract

Interferon Regulatory Factor 4 (IRF4) and IRF8 are critical regulators of immune system development and function. In B lymphocytes, IRF4 and IRF8 have been shown to control important events during their development and maturation including pre-B cell differentiation, induction of B cell tolerance pathways, marginal zone B cell development, germinal center reaction and plasma cell differentiation. Mechanistically, IRF4 and IRF8 are found to function redundantly to control certain stages of B cell development, but in other stages, they function nonredundantly to play distinct roles in B cell biology. In line with their essential roles in B cell development, deregulated expressions of IRF4 and IRF8 have been associated to the pathogenesis of several B cell malignancies and diseases. Recent studies have elucidated diverse transcriptional networks regulated by IRF4 and IRF8 at distinct B cell developmental stages and related malignancies. In this review we will discuss the recent advances for the roles of IRF4 and IRF8 during B cell development and associated diseases.

Entities:  

Year:  2014        PMID: 25506356      PMCID: PMC4261187          DOI: 10.1007/s11515-014-1318-y

Source DB:  PubMed          Journal:  Front Biol (Beijing)        ISSN: 1674-7984


  113 in total

1.  A developmentally controlled competitive STAT5-PU.1 DNA binding mechanism regulates activity of the Ig κ E3' enhancer.

Authors:  Suchita Hodawadekar; Kyoungsook Park; Michael A Farrar; Michael L Atchison
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

2.  Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells.

Authors:  Adriana Forero; Patrick S Moore; Saumendra N Sarkar
Journal:  J Immunol       Date:  2013-06-26       Impact factor: 5.422

3.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Authors:  Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

4.  Transcriptional control of adipose lipid handling by IRF4.

Authors:  Jun Eguchi; Xun Wang; Songtao Yu; Erin E Kershaw; Patricia C Chiu; Joanne Dushay; Jennifer L Estall; Ulf Klein; Eleftheria Maratos-Flier; Evan D Rosen
Journal:  Cell Metab       Date:  2011-03-02       Impact factor: 27.287

5.  Control of autophagic cell death by caspase-10 in multiple myeloma.

Authors:  Laurence Lamy; Vu N Ngo; N C Tolga Emre; Arthur L Shaffer; Yandan Yang; Erming Tian; Vinod Nair; Michael J Kruhlak; Adriana Zingone; Ola Landgren; Louis M Staudt
Journal:  Cancer Cell       Date:  2013-03-28       Impact factor: 31.743

6.  Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2.

Authors:  Daniel Portal; Hufeng Zhou; Bo Zhao; Peter V Kharchenko; Elizabeth Lowry; Limsoon Wong; John Quackenbush; Dustin Holloway; Sizun Jiang; Yong Lu; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

7.  Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization.

Authors:  Haixia Xu; Jimmy Zhu; Sinead Smith; Julia Foldi; Baohong Zhao; Allen Y Chung; Hasina Outtz; Jan Kitajewski; Chao Shi; Silvio Weber; Paul Saftig; Yueming Li; Keiko Ozato; Carl P Blobel; Lionel B Ivashkiv; Xiaoyu Hu
Journal:  Nat Immunol       Date:  2012-05-20       Impact factor: 25.606

8.  IRF4 is a suppressor of c-Myc induced B cell leukemia.

Authors:  Simanta Pathak; Shibin Ma; Long Trinh; James Eudy; Kay-Uwe Wagner; Shantaram S Joshi; Runqing Lu
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

9.  IRF4 is a novel mediator for neuronal survival in ischaemic stroke.

Authors:  S Guo; Z-Z Li; D-S Jiang; Y Y Lu; Y Liu; L Gao; S-M Zhang; H Lei; L-H Zhu; X-D Zhang; D-P Liu; H Li
Journal:  Cell Death Differ       Date:  2014-02-07       Impact factor: 15.828

10.  Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Maurizio Affer; Marta Chesi; Wei-Dong G Chen; Jonathan J Keats; Yulia N Demchenko; Anna V Roschke; Scott Van Wier; Rafael Fonseca
Journal:  Leukemia       Date:  2014-02-12       Impact factor: 11.528

View more
  13 in total

1.  Inferring a role for methylation of intergenic DNA in the regulation of genes aberrantly expressed in precursor B-cell acute lymphoblastic leukemia.

Authors:  Md Almamun; Olha Kholod; Alexei J Stuckel; Benjamin T Levinson; Nathan T Johnson; Gerald L Arthur; J Wade Davis; Kristen H Taylor
Journal:  Leuk Lymphoma       Date:  2017-01-17

2.  The molecular basis for the development of adult T-cell leukemia/lymphoma in patients with an IRF4K59R mutation.

Authors:  Srinivasan Sundararaj; Sandali Seneviratne; Simon J Williams; Anselm Enders; Marco G Casarotto
Journal:  Protein Sci       Date:  2022-02-15       Impact factor: 6.725

3.  Enhancer jungles establish robust tissue-specific regulatory control in the human genome.

Authors:  Shan Li; Ivan Ovcharenko
Journal:  Genomics       Date:  2019-12-27       Impact factor: 5.736

Review 4.  Molecular interactions of IRF4 in B cell development and malignancies.

Authors:  Srinivasan Sundararaj; Marco G Casarotto
Journal:  Biophys Rev       Date:  2021-08-13

5.  Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma.

Authors:  Yulian Xu; Lei Jiang; Jianchen Fang; Rong Fang; Herbert C Morse; Guifang Ouyang; Jeff X Zhou
Journal:  J Cancer       Date:  2015-08-07       Impact factor: 4.207

6.  Interferon regulatory factor 4 attenuates Notch signaling to suppress the development of chronic lymphocytic leukemia.

Authors:  Vipul Shukla; Ashima Shukla; Shantaram S Joshi; Runqing Lu
Journal:  Oncotarget       Date:  2016-07-05

7.  Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.

Authors:  Weijie Zhong; Xin Xu; Zhigang Zhu; Qinghua Du; Hong Du; Li Yang; Yanying Ling; Huabao Xiong; Qingshan Li
Journal:  Oncotarget       Date:  2017-07-25

8.  Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation.

Authors:  Venetia Bigley; Sheetal Maisuria; Urszula Cytlak; Laura Jardine; Matthew A Care; Kile Green; Merry Gunawan; Paul Milne; Rachel Dickinson; Sarah Wiscombe; David Parry; Rainer Doffinger; Arian Laurence; Claudia Fonseca; Oda Stoevesandt; Andrew Gennery; Andrew Cant; Reuben Tooze; A John Simpson; Sophie Hambleton; Sinisa Savic; Gina Doody; Matthew Collin
Journal:  J Allergy Clin Immunol       Date:  2017-11-08       Impact factor: 10.793

9.  In Silico Analysis of Possible Interaction between Host Genomic Transcription Factors (TFs) and Zika Virus (ZikaSPH2015) Strain with Combinatorial Gene Regulation; Virus Versus Host-The Game Reloaded.

Authors:  Massimiliano Chetta; Marina Tarsitano; Laura Vicari; Annalisa Saracino; Nenad Bukvic
Journal:  Pathogens       Date:  2021-01-14

10.  Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression.

Authors:  L C Stetson; Dheepa Balasubramanian; Susan Pereira Ribeiro; Tammy Stefan; Kalpana Gupta; Xuan Xu; Slim Fourati; Anne Roe; Zachary Jackson; Robert Schauner; Ashish Sharma; Banumathi Tamilselvan; Samuel Li; Marcos de Lima; Tae Hyun Hwang; Robert Balderas; Yogen Saunthararajah; Jaroslaw Maciejewski; Thomas LaFramboise; Jill S Barnholtz-Sloan; Rafick-Pierre Sekaly; David N Wald
Journal:  Leukemia       Date:  2021-07-09       Impact factor: 12.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.